Overexpressed Raf-1 and phosphorylated cyclic adenosine 3′-5′-monophosphatate response element-binding protein are early markers for lung adenocarcinoma

Cancer

Volumn 109, Issue 6, 2007, Pages 1164-1173

  Cekanova, Maria ^a   Majidy, Mourad ^a   Masi, Thomas ^a   Al Wadei, Hussein A N ^a   Schuller, Hildegard M ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Early markers; Hamster model; Human tissue arrays; Phosphorylated cyclic adenosine 3 5 monophosphatate response element binding protein; Pulmonary adenocarcinoma; Raf 1

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; BETA 1 ADRENERGIC RECEPTOR; CARCINOGEN; CYCLIC AMP BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; NITROSAMINE; RAF PROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; MICROADENOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; RESPIRATORY EPITHELIUM; SYRIAN HAMSTER; TISSUE MICROARRAY; TRANSACTIVATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; CRICETINAE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EARLY DIAGNOSIS; HUMANS; LUNG NEOPLASMS; MALE; MICRODISSECTION; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-RAF; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33947253249     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22520     Document Type: Article

References (22)

1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276-1299.
2. Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer. 2005;116:963-971.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
4. Khuri FR, Glisson BS, Kim ES, et al. Phase I study of the farnesyl transferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004;10:2968-2976.
5. Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des. 2002;8:2269-2278.
6. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001;98:13784-13789.
7. Plopper CG, Hill LH, Mariassy AT. Ultrastructure of the nonciliated bronchiolar epithelial (Clara) cell of mammalian lung. III. A study of man with comparison of 15 mammalian species. Exp Lung Res. 1980;1:171-180.
8. Reznik-Schuller HM. The respiratory tract in rodents. In:Reznik-Schuller HM, ed, Comparative Respiratory Tract Carcinogenesis, Ed. 1, vol 1. Boca Raton, FL: CRC Press; 1983:79-94.
9. Schuller HM, Witschi HP, Nylen E, et al. Pathobiology of lung tumors induced in hamsters by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the modulating effect of hyperoxia. Cancer Res. 1990;50:1960-1965.
10. Oreffo VI, Lin HW, Padmanabhan R, Witschi H. K-ras and p53 point mutations in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced hamster lung tumors. Carcinogenesis. 1993;14:451-455.
11. Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res. 1999;424(1-2):127-142.
12. Schuller HM, Tithof PK, Williams M, Plummer H 3rd. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 1999;59:4510-4515.
13. Laag E, Majidi M, Cekanova M, et al. NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. Int J Cancer. 2006;119:1547-1552.
14. Schuller HM, Porter B, Riechert A. Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol. 2000;126:624-630.
15. Schuller HM, Cekanova M. NNK-induced hamster lung adenocarcinomas over-express beta2-adrenergic and EGFR signaling pathways. Lung Cancer. 2005;49:35-45.
16. Gandara DR, West H, Chansky K, et al. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004;10(12 pt 2):4205s-4209s.
17. Al-Wadei HA, Takahasi T, Schuller HM. PKA-dependent growth stimulation of cells derived from human pulmonary adenocarcinoma and small airway epithelium by dexamethasone. Eur J Cancer. 2005;41:2745-2753.
18. Belinsky SA, Devereux TR, White CM, et al. Role of Clara cells and type II cells in the development of pulmonary tumors in rats and mice following exposure to a tobacco-specific nitrosamine. Exp Lung Res. 1991;17:263-278.
19. Rosenberg D, Groussin L, Jullian E, et al. Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. Ann N Y Acad Sci. 2002;968:65-74.
20. Wallukat G. The beta-adrenergic receptors. Herz. 2002;27:683-690.
21. Fenaroli A, Vujanac M, De Cesare D, Zimarino V. A small-scale survey identifies selective and quantitative nucleo-cytoplasmic shuttling of a subset of CREM transcription factors. Exp Cell Res. 2004;299:209-226.
22. Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393-401.